EGFR and hepatocellular carcinoma: For example, aberrant EGFR activation mediates sorafenib resistance in HCC, which may be potentiated by an EGFR-KLF4 positive feedback loop (Blivet-Van Eggelpoël et al., 2012; Pang et al., 2019), while polymorphisms in VEGFA and VEGFC similarly confer sorafenib resistance (Scartozzi et al., 2014).